Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal hypertension in MASH cirrhosisBlinded central review ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver ...

Readouts from Novo Nordisk and Viking Therapeutics at AASLD 2024 strengthen the argument for GLP-1 therapies as an emerging ...

Among 64 patients who received immune checkpoint inhibitors, 78% had downstaging of their liver tumor to within Milan ...

Since MELD 3.0 was implemented in July 2023, a higher proportion of women are now on the liver transplant waitlist, and ...

today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held ...

Vir Biotechnology (VIR) announced results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with ...

A recent study has sounded the alarm for beer lovers, suggesting that their food choices might not be up to par with those ...

A study has found that people who only drink lager or bitter eat lower-quality food, are less active, and are more likely to ...

While having HDL levels above 60 mgdL is often seen as a sign of good health it’s not a standalone indicator Read ahead to ...